- Home
- ICCC vs AVTX Comparison
ICCC vs AVTX Comparison
Compare ICCC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- AVTX
- Stock Information
- Founded
- ICCC 1982
- AVTX 2011
- Country
- ICCC United States
- AVTX United States
- Employees
- ICCC N/A
- AVTX N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- AVTX Health Care
- Exchange
- ICCC Nasdaq
- AVTX Nasdaq
- Market Cap
- ICCC 60.1M
- AVTX 57.4M
- IPO Year
- ICCC 1987
- AVTX 2015
- Fundamental
- Price
- ICCC $6.71
- AVTX $5.09
- Analyst Decision
- ICCC
- AVTX Strong Buy
- Analyst Count
- ICCC 0
- AVTX 7
- Target Price
- ICCC N/A
- AVTX $31.00
- AVG Volume (30 Days)
- ICCC 41.8K
- AVTX 122.3K
- Earning Date
- ICCC 08-12-2025
- AVTX 08-11-2025
- Dividend Yield
- ICCC N/A
- AVTX N/A
- EPS Growth
- ICCC N/A
- AVTX N/A
- EPS
- ICCC N/A
- AVTX N/A
- Revenue
- ICCC $27,302,766.00
- AVTX $441,000.00
- Revenue This Year
- ICCC N/A
- AVTX N/A
- Revenue Next Year
- ICCC N/A
- AVTX N/A
- P/E Ratio
- ICCC N/A
- AVTX $0.74
- Revenue Growth
- ICCC 28.29
- AVTX N/A
- 52 Week Low
- ICCC $3.34
- AVTX $3.39
- 52 Week High
- ICCC $7.60
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- ICCC 49.68
- AVTX 57.49
- Support Level
- ICCC $5.63
- AVTX $4.76
- Resistance Level
- ICCC $7.14
- AVTX $5.05
- Average True Range (ATR)
- ICCC 0.64
- AVTX 0.30
- MACD
- ICCC -0.06
- AVTX 0.03
- Stochastic Oscillator
- ICCC 42.58
- AVTX 84.75
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).